CB1R-dependent mitochondrial biogenesis may contribute to the antidepressant effects of esketamine in a chronic variable stress male mouse model.
Wei Zhao, Xinxin Zhao, Yunyun Zhang, Xinxu Ma, Chun Huang, Guangchao Zhao, Shiquan Wang, Huaning Wang, Zhengwu Peng, Min Cai
Neuroscience July 27, 2026 DOI: 10.1016/j.neuroscience.2026.07.059 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Mice subjected to chronic variable stress |
| Interventions | Esketamine AM251 SR141716A |
| Dose | 15 mg/kg esketamine |
| Duration | 21 days of stress; single injection 24 hours before testing |
| Measures | Forced swim test, tail suspension test, novelty-suppressed feeding test, Western blotting |
| Topics | Esketamine |
| Keywords | Cb1 receptor Chronic variable stress Hippocampus Mitochondrial biogenesis |
| Key findings | Esketamine reversed depressive-like behaviors and normalized hippocampal CB1R, NRF1, and TFAM expression in stressed mice, but CB1R antagonists blocked these effects, indicating CB1R-dependent mitochondrial biogenesis changes underlie its rapid antidepressant action. |
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete efficacy. Esketamine produces antidepressant effects more rapidly than conventional treatments, but its underlying mechanisms remain unclear. We examined whether cannabinoid type 1 receptor (CB1R) signaling is associated with hippocampal mitochondrial biogenesis-related changes following esketamine treatment in a chronic variable stress (CVS) mouse model. Mice underwent 21 days of CVS and received a single intraperitoneal injection of esketamine (15 mg/kg) 24 h before behavioral testing. Hippocampal CB1R, nuclear respiratory factor 1 (NRF1), mitochondrial transcription factor A (TFAM), and total cytochrome C expression were assessed by Western blotting. Additional groups received the CB1R antagonists AM251 or SR141716A before esketamine administration. CVS induced depressive-like behavioral changes in the forced swim, tail suspension, and novelty-suppressed feeding tests. These effects were accompanied by reduced hippocampal CB1R, NRF1, and TFAM expression and altered total cytochrome c expression. Esketamine reversed the behavioral abnormalities and normalized these molecular changes. Pretreatment with either CB1R antagonist prevented both the behavioral and molecular effects of esketamine. These findings indicate that the antidepressant-like effects of esketamine observed 24 h after administration are associated with CB1R-dependent changes in hippocampal mitochondrial biogenesis-related protein expression. Further studies using direct mitochondrial functional assays and loss-of-function approaches are needed to establish causality.
Comparable studies
Other preclinical and animal studies on esketamine, most cited first.
Citations in the library
Cites 19
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex Journal of Neuroscience October 24, 2007
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Molecular Psychiatry May 7, 2021
- Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal of Psychiatry March 3, 2021
and 14 more in the library